Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Amgen Highlights New COPD, Asthma and Vasculitis Research at ATS 2024
Amgen Highlights New COPD, Asthma and Vasculitis Research at ATS 2024
Amgen Highlights New COPD, Asthma and Vasculitis Research at ATS 2024
Submitted by
admin
on May 1, 2024 - 9:31am
Source:
BioSpace
News Tags:
Amgen
Tezspire
COPD
AMG104
severe asthma
Tavneos
vasculitits
R&D
ATS
Headline:
Amgen Highlights New COPD, Asthma and Vasculitis Research at ATS 2024
snippet:
Findings From Tezspire® (tezepelumab-ekko) Phase 2a COURSE COPD Study
Phase 1 Study on AMG104/AZD8630 (Inhaled Anti-TSLP) in Moderate to Severe Asthma
New TAVNEOS® (avacopan) Data in Adults With Severe Active ANCA-Associated Vasculitis With Lung Involvement
Do Not Allow Advertisers to Use My Personal information
